SpineGuard SA provided sales guidance for the second half of 2024. In the second half of 2024, the company intends to continue its sales drive, particularly in the United States, and market rollout of three new products embedding DSG® technology and satisfying unmet clinical needs (the PediGuard Threaded adapted to scoliosis correction via anterior approach, the PediGuard Canulated designed for sacroiliac fusion, and the DSG Sensor Drill Bit compatible with power drills and surgical navigation in the spine) in order to sustain double-digit growth in the coming quarters.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1582 EUR | +0.76% |
|
-6.94% | -20.74% |
07-15 | SpineGuard SA Reports Consolidated Revenue Results for the Second Quarter and First Half of 2024 | CI |
07-15 | SpineGuard SA Provides Sales Guidance for the Second Half of 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-20.74% | 9.15M | |
+75.69% | 12.57B | |
-23.80% | 7.4B | |
-7.11% | 5.95B | |
+6.54% | 5.05B | |
+17.15% | 4.29B | |
-15.13% | 4.12B | |
-15.59% | 3.16B | |
-1.73% | 2.01B | |
+20.50% | 1.93B |
- Stock Market
- Equities
- ALSGD Stock
- News SpineGuard
- SpineGuard SA Provides Sales Guidance for the Second Half of 2024